PLGA nanoparticles and nanosuspensions with amphotericin B: Potent in vitro and in vivo alternatives to Fungizone and AmBisome

Journal of Controlled Release

Volumn 161, Issue 3, 2012, Pages 795-803

  Van De Ven, H ^a   Paulussen, C ^a   Feijens, P B ^a   Matheeussen, A ^a   Rombaut, P ^b   Kayaert, P ^b   Van Den Mooter, G ^b   Weyenberg, W ^a   Cos, P ^a   Maes, L ^a   Ludwig, A ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Amphotericin B; Fungal infection; Nanomedicines; Nanosuspension; PLGA nanoparticles

Indexed keywords

AMPHOTERICIN B; FUNGAL INFECTION; NANO-SUSPENSIONS; NANOMEDICINES; PLGA NANOPARTICLES;

ASPERGILLUS; BIOACTIVITY; ENZYME INHIBITION; ZETA POTENTIAL;

NANOPARTICLES;

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CHOLIC ACID; NANOPARTICLE; POLOXAMER; POLYGLACTIN; POLYSORBATE 80; POLYVINYL ALCOHOL;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG POTENCY; ERYTHROCYTE; FEMALE; FUNGICIDAL ACTIVITY; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA INFANTUM; MORPHOLOGY; MOUSE; NANOFORMULATION; NANOMEDICINE; NANOPHARMACEUTICS; NANOPRECIPITATION; NANOSUSPENSION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROMASTIGOTE; TRICHOPHYTON RUBRUM; ZETA POTENTIAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CELL LINE; COLONY COUNT, MICROBIAL; ERYTHROCYTES; FEMALE; FUNGI; HEMOLYSIS; HUMANS; KIDNEY; LACTIC ACID; LEISHMANIA INFANTUM; LIPOSOMES; LIVER; MICE; NANOPARTICLES; POLYGLYCOLIC ACID; SPLEEN;

EID: 84864591366     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.05.037     Document Type: Article

References (51)

1. J.P. Adler-Moore, and R.T. Proffitt Amphotericin B lipid preparations: what are the differences Clin. Microbiol. Infect. 14 S4 2008 25 36 (Pubitemid 351593914)
2. J.J. Torrado, R. Espada, M.P. Ballesteros, and S. Torrado-Santiago Amphotericin B formulations and drug targeting J. Pharm. Sci. 97 7 2008 2405 2425
3. H.C. Maltezou Drug resistance in visceral leishmaniasis J. Biomed. Biotechnol. 2010 2010 1 8
4. M. Baginski, and J. Czub Amphotericin B and its new derivatives - mode of action Curr. Drug Metab. 10 2009 459 469
5. B.E. Cohen Amphotericin B membrane action: role for two types of ion channels in eliciting cell survival and lethal effects J. Membr. Biol. 238 2010 1 20
6. J. Golenser, and A. Domb New formulations and derivatives of amphotericin B for treatment of leishmaniasis Mini Rev. Med. Chem. 6 2006 153 162
7. S.P. Vyas, and S. Gupta Optimizing efficacy of amphotericin B through nanomodification Int. J. Nanomedicine 1 4 2006 417 432
8. A. Lemke, A.F. Kiderlen, and O. Kayser Amphotericin B Appl. Microbiol. Biotechnol. 68 2005 151 162 (Pubitemid 41110936)
9. L.S.S. Guo Amphotericin B colloidal dispersion: an improved antifungal therapy Adv. Drug Deliv. Rev. 47 2001 149 163 (Pubitemid 32324112)
10. A. Antoniadou, and B. Dupont Lipid formulations of amphotericin B: where are we today J. Med. Mycol. 15 2005 230 238 (Pubitemid 41774269)
11. M. Kleinberg What is the current and future status of conventional amphotericin B Int. J. Antimicrob. Agents 27S 2006 S12 S16
12. S.H. Jung, D.H. Lim, S.H. Jung, J.E. Lee, K.-S. Jeong, H. Seong, and B.C. Shin Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics Eur. J. Pharm. Sci. 37 2009 313 320
13. 3-PLA copolymers: an in vivo evaluation in a murine model Mol. Pharm. 8 1 2011 204 212
14. V.K. Prajapati, K. Awasthi, S. Gautam, T.P. Yadav, M. Rai, O.N. Srivastava, and S. Sundar Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes J. Antimicrob. Chemother. 66 2011 874 879
15. R.H. Müller, S. Gohla, and C.M. Keck State of the art of nanocrystals - special features, production, nanotoxicology aspects and intracellular delivery Eur. J. Pharm. Biopharm. 78 2011 1 9
16. M. Vermeersch, R. Inocêncio da Luz, K. Toté, J.-P. Timmermans, P. Cos, and L. Maes In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences Antimicrob. Agents Chemother. 53 9 2009 3855 3859
17. H. Van de Ven, M. Vermeersch, A. Matheeussen, J. Vandervoort, W. Weyenberg, S. Apers, P. Cos, L. Maes, and A. Ludwig PLGA nanoparticles loaded with the antileishmanial saponin β-aescin: factor influence study and in vitro efficacy evaluation Int. J. Pharm. 420 1 2011 122 132
18. S. Gelperina, O. Maksimenko, A. Khalansky, L. Vanchugova, E. Shipulo, K. Abbasova, R. Berdiev, S. Wohlfart, N. Chepurnova, and J. Kreuter Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters Eur. J. Pharm. Biopharm. 74 2010 157 163
19. J.L. Italia, M.M. Yahya, D. Singh, and M.N.V. Ravi Kumar Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone® Pharm. Res. 26 6 2009 1324 1331
20. M. Holzer, V. Vogel, W. Mäntele, D. Schwartz, W. Haase, and K. Langer Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage Eur. J. Pharm. Biopharm. 72 2009 428 437
21. P. Legrand, M. Chéron, L. Leroy, and J. Bolard Release of amphotericin B from delivery systems and its action against fungal and mammalian cells J. Drug Target. 4 5 1997 311 319 (Pubitemid 27239019)
22. K. de Wit, C. Paulussen, A. Matheeussen, K. van Rossem, P. Cos, and L. Maes In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models Antimicrob. Agents Chemother. 54 11 2010 4927 4929
23. S. Galindo-Rodriguez, E. Allémann, H. Fessi, and E. Doelker Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods Pharm. Res. 21 8 2004 1428 1439 (Pubitemid 39149658)
24. U. Bilati, E. Allémann, and E. Doelker Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles Eur. J. Pharm. Sci. 24 2005 67 75 (Pubitemid 40051288)
25. R.H. Müller, C. Jacobs, and O. Kayser Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future Adv. Drug Deliv. Rev. 47 2001 3 19 (Pubitemid 32209229)
26. F. Gaboriau, M. Chéron, C. Petit, and J. Bolard Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index Antimicrob. Agents Chemother. 41 11 1997 2345 2351 (Pubitemid 27467538)
27. R. Espada, S. Valdespina, C. Alfonso, G. Rivas, M.P. Ballesteros, and J.J. Torrado Effect of aggregation state on the toxicity of different amphotericin B preparations Int. J. Pharm. 361 2008 64 69
28. S. Jullien, A. Contrepois, J.E. Sligh, Y. Domart, P. Yeni, J. Brajtburg, G. Medoff, and J. Bolard Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids Antimicrob. Agents Chemother. 33 3 1989 345 349 (Pubitemid 19071969)
29. K.K. Nishi, M. Antony, P.V. Mohanan, T.V. Anilkumar, P.M. Loiseau, and A. Jayakrishnan Amphotericin B-gum Arabic conjugates: synthesis, toxicity, bioavailability, and activities against Leishmania and fungi Pharm. Res. 24 5 2007 971 980 (Pubitemid 46675399)
30. H. Fessi, F. Puisieux, J.P. Devissaguet, N. Ammoury, and S. Benita Nanocapsule formation by interfacial polymer deposition following solvent displacement Int. J. Pharm. 55 1989 R1 R4
31. C. Vauthier, and K. Bouchemal Methods for the preparation and manufacture of polymeric nanoparticles Pharm. Res. 26 5 2009 1025 1058
32. H.S. Yoo, H.-K. Choi, and T.G. Park Protein-fatty acid complex for enhanced loading and stability within biodegradable nanoparticles J. Pharm. Sci. 90 2 2001 194 201 (Pubitemid 32158047)
33. M.S. Espuelas, P. Legrand, M. Cheron, G. Barratt, F. Puisieux, M.J. Renedo, J.-P. Devissaguet, and J.M. Irache Interaction of amphotericin B with polymeric colloids: 2. Effect of poloxamer on the adsorption of amphotericin B onto poly(ε-caprolactone) nanospheres Colloids Surf. B Biointerfaces 11 1998 203 212 (Pubitemid 28393980)
34. D. Quintanar-Guerrero, A. Ganem-Quintanar, E. Allémann, H. Fessi, and E. Doelker Influence of the stabilizer coating layer on the purification and freeze-drying of poly(D, L-lactic acid) nanoparticles prepared by an emulsion-diffusion technique J. Microencapsul. 15 1 1998 107 119 (Pubitemid 28031795)
35. M.J. Santander-Ortega, A.B. Jódar-Reyes, N. Csaba, D. Bastos-González, and J.L. Ortega-Vinuesa Colloidal stability of Pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms J. Colloid Interface Sci. 302 2006 522 529 (Pubitemid 44348977)
36. S. Verma, R. Gokhale, and D.J. Burgess A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions Int. J. Pharm. 380 2009 216 222
37. W. Abdelwahed, G. Degobert, S. Stainmesse, and H. Fessi Freeze-drying of nanoparticles: formulation, process and storage considerations Adv. Drug Deliv. Rev. 58 2006 1688 1713 (Pubitemid 44827432)
38. M.S. Espuelas, P. Legrand, M. Cheron, G. Barratt, F. Puisieux, J.-P. Devissaguet, and J.M. Irache Interaction of amphotericin B with polymeric colloids. A spectroscopic study Colloids Surf. B Biointerfaces 11 1998 141 151 (Pubitemid 28381121)
39. M.S. Espuelas, P. Legrand, J.M. Irache, C. Gamazo, A.M. Orecchioni, J.P. Devissaguet, and P. Ygartua Poly(ε-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity Int. J. Pharm. 158 1997 19 27 (Pubitemid 27504470)
40. P. Legrand, A. Vertut-Doï, and J. Bolard Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line J. Antimicrob. Chemother. 37 1996 519 533 (Pubitemid 26116967)
41. J. Brajtburg, and J. Bolard Carrier effects on biological activity of amphotericin B Clin. Microbiol. Rev. 9 4 1996 512 531 (Pubitemid 26366536)
42. J. Adler-Moore, and R.T. Proffitt Am Bisome: liposomal formulation, structure, mechanism of action and pre-clinical experience J. Antimicrob. Chemother. 49 S1 2002 21 30 (Pubitemid 34162653)
43. K. Shimizu, M. Osada, K. Takemoto, Y. Yamamoto, T. Asai, and N. Oku Temperature-dependent transfer of amphotericin B from liposomal membrane of Am Bisome to fungal cell membrane J. Control. Release 141 2010 208 215
44. M. Tsai, Z. Lu, J. Wang, T.-K. Yeh, M.G. Wientjes, and J.L.-S. Au Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel Pharm. Res. 24 9 2007 1691 1701 (Pubitemid 47206619)
45. S. Dadashzadeh, N. Mirahmadi, M.H. Babaei, and A.M. Vali Peritoneal retention of liposomes: effects of lipid composition, PEG coating and liposome charge J. Control. Release 148 2010 177 186
46. N. Mirahmadi, M.H. Babaei, A.M. Vali, and S. Dadashzadeh Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice Int. J. Pharm. 383 2010 7 13
47. I. Bekersky, R.M. Fielding, D.E. Dressler, J.W. Lee, D.N. Buell, and T.J. Walsh Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate Antimicrob. Agents Chemother. 46 3 2002 834 840 (Pubitemid 34157671)
48. A. Nagayasu, K. Uchiyama, and H. Kiwada The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs Adv. Drug Deliv. Rev. 40 1999 75 87 (Pubitemid 29486605)
49. J.-P. Latgé Aspergillus fumigatus and aspergillosis Clin. Microbiol. Rev. 12 2 1999 310 350 (Pubitemid 29196856)
50. J. Wong, A. Brugger, A. Khare, M. Chaubal, P. Papadopoulos, B. Rabinow, J. Kipp, and J. Ning Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects Adv. Drug Deliv. Rev. 60 2008 939 954
51. A. Lemke, A.F. Kiderlen, B. Petri, and O. Kayser Delivery of amphotericin B nanosuspensions to the brain and determination of activity against Balamuthia mandrillaris amebas Nanomedicine 6 2010 597 603